A study found that the Respiratory syncytial virus prefusion F (RSVpreF) vaccine significantly reduced severe RSV-related lower respiratory tract disease in older adults, with an efficacy of 91% when compared to a strictly defined control group. The vaccine also showed an efficacy of 90% when compared to a broad control group. Researchers analyzed data from a large US healthcare network, including 7047 older adults, with 223 receiving the RSVpreF vaccine and testing positive for RSV. The vaccine was found to prevent one RSV-related ED or hospitalization encounter for every 250 persons vaccinated in the first season. The study was funded by Pfizer, and some authors disclosed financial ties to the company.
Source link
RSV Vaccine Protects Older Adults From Severe Disease
